New shot could tame seasonal sniffles for good?

NCT ID NCT07398859

Symptom relief Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an injection called TQH2722 in 300 adults with seasonal allergic rhinitis (hay fever). The goal is to see if it safely eases symptoms like sneezing, stuffy nose, and itchy eyes when added to standard allergy treatments. Participants will receive the injection and be monitored for side effects and symptom improvement during pollen season.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18-75, with no gender restrictions. * Diagnosed with seasonal allergic rhinitis. * Positive allergen test result. * The subjects have sufficient exposure to pollen during the pollen season. * The subject's medical history indicates that the subject had poor control of Seasonal Allergic Rhinitis (SAR) symptoms during the previous pollen season or the subject was dissatisfied with the subjective symptom control. * Screen for subjects who have a morning iTNSS score of ≥4 on the day of screening; at baseline visit, have a morning iTNSS score of ≥4, and have an average rTNSS score of ≥4 over the past 6 days. * Good compliance during screening/induction period. * Subjects with comorbid asthma should have stable medication use before the screening period and have their asthma condition assessed as stable by the investigator or specialist. * The subjects voluntarily joined this study, signed the informed consent form, and exhibited good compliance. * The subjects and their partners agree to take effective contraceptive measures throughout the entire study period (from the signing of the Informed Consent Form (ICF) to 3 months after the last administration of the trial drug). Exclusion Criteria: * Any abnormal laboratory test value during the screening period or randomization. * Any disease that researchers consider to be unstable and may affect the patient's safety throughout the entire study period, or affect the study results or their interpretation, or hinder the patient's ability to complete the entire study process. * Patients with active autoimmune diseases. * Known or suspected immunosuppressants. * Subjects with active malignant tumors or a history of malignant tumors. * Screen for individuals with a history of active tuberculosis within the previous 12 months. * During the screening period, there is active hepatitis, or the presence of human immunodeficiency virus antibody (Anti-HIV) positivity, or syphilis treponema antibody (Anti-TP) positivity. * Screen for cases diagnosed with helminthic parasitic infections within the previous 6 months, who have not undergone standard treatment or have experienced ineffective standard treatment. * Subjects who have received specific medications or undergone any nasal or sinus surgery within the specified timeframe. * Intravenous immunoglobulin (IVIG) therapy and/or plasma exchange within 30 days before screening. * Screen subjects who have used monoamine oxidase inhibitors within the previous 14 days. * Initiate allergen immunotherapy within 3 months prior to screening. * Screen for individuals who have received attenuated live vaccines within the previous 4 weeks or plan to receive attenuated live vaccines during the study period. * Screen for systemic Chinese herbal preparations used for the treatment of AR with short- or medium-acting systemic glucocorticoids within 4 weeks, or screen for long-acting Systemic Corticosteroids (SCS) received within the previous 6 weeks. * Suffering from chronic active or acute infection within 2 weeks before screening or during the screening and import period. * Patients with concomitant asthma should be excluded if they meet any of the following conditions: a. forced expiratory volume in one second (FEV1) ≤ 50% of the predicted normal value; b. acute exacerbation of asthma within 90 days prior to screening; c. currently using fluticasone propionate at a daily dose of \>1000 μg/day or equivalent doses of other inhaled corticosteroids; d. assessed by the investigator or specialist as having unstable asthma. * The subject has a concomitant disease that renders them unable to complete the screening period assessment or evaluate the primary efficacy endpoint. * Suffering from malignant and benign tumors in the nasal cavity. * Subjects with perennial allergic rhinitis (PAR) who are allergic to pet hair. * Unable to use nasal corticosteroid sprays or antihistamines. * Have a history of systemic allergy to any biological agents. * Women who are pregnant or breastfeeding. * Individuals who abuse alcohol, use drugs, and have known drug dependency. * History of major organ transplantation or hematopoietic stem cell/bone marrow transplantation. * According to the researcher's judgment, there are any medical or psychiatric symptoms that may put the subjects at risk, interfere with their participation in the study, or interfere with the interpretation of the study results. * The forced expiratory volume in one second (FEV1) of the subject is less than or equal to 50% of the predicted normal value. * Other reasons why the researcher believes it is inappropriate to participate in this trial.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

seasonal allergic rhinitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Seasonal allergic rhinitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

The places running it

30 sites. The list below names each one and where it is.
The official record

ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

Open the record ↗
A doctor treating you

A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

Cangzhou Central Hospital
NOT_YET_RECRUITING

Cangzhou, Hebei, 061017, China
Hebei Medical University Third Hospital
NOT_YET_RECRUITING

Shijiazhuang, Hebei, 50000, China
Hebei PetroChina Central Hospital
NOT_YET_RECRUITING

Langfang, Hebei, 65000, China
Hebei Provincial People's Hospital
NOT_YET_RECRUITING

Shijiazhuang, Hebei, 050051, China
Hebei University Affiliated Hospital
NOT_YET_RECRUITING

Baoding, Hebei, 071000, China
Henan Provincial People's Hospital
NOT_YET_RECRUITING

Zhengzhou, Henan, 450000, China
Hospital of Chengdu University of Traditional Chinese Medicine
NOT_YET_RECRUITING

Chengdu, Sichuan, 610000, China
Peking University First Hospital
NOT_YET_RECRUITING

Beijing, Beijing Municipality, 100034, China
Peking University People's Hospital
NOT_YET_RECRUITING

Beijing, Beijing Municipality, 100044, China
Peking University Third Hospital
RECRUITING

Beijing, Beijing Municipality, 100191, China
Qilu Hospital of Shandong University
NOT_YET_RECRUITING

Jinan, Shandong, 250012, China
Second People's Hospital of Chengdu
NOT_YET_RECRUITING

Chengdu, Sichuan, 610000, China
Shandong Second Provincial General Hospital
NOT_YET_RECRUITING

Jinan, Shandong, 250000, China
Shanxi Bethune Hospital
RECRUITING

Taiyuan, Shanxi, 030000, China
The Central Hospital of Wuhan
NOT_YET_RECRUITING

Wuhan, Hubei, 430014, China
The First Affiliated Hospital of Chongqing Medical University
RECRUITING

Chongqing, Chongqing Municipality, 400010, China
The First Affiliated Hospital of Hebei North University
NOT_YET_RECRUITING

Zhangjiakou, Hebei, 075000, China
The First Affiliated Hospital of Kunming Medical University
NOT_YET_RECRUITING

Kunming, Yunnan, 650032, China
The First Affiliated Hospital of Xi'an Jiaotong University
NOT_YET_RECRUITING

Xi'an, Shaanxi, 710061, China
The First Affiliated Hospital of Xinjiang Medical University
NOT_YET_RECRUITING

Ürümqi, Xinjiang, China
The Second Affiliated Hospital of Xi'an Jiaotong University
NOT_YET_RECRUITING

Xi'an, Shaanxi, 710004, China
Tianjin People's Hospital
NOT_YET_RECRUITING

Tianjin, Tianjin Municipality, 300121, China
Tongji Hospital of Tongji medical college of HUST
NOT_YET_RECRUITING

Wuhan, Hubei, 430030, China
Union Hospital, Tongji Medical College, Huazhong University of science and technology
NOT_YET_RECRUITING

Wuhan, Hubei, 430022, China
Yan'an University Xianyang Hospital
NOT_YET_RECRUITING

Xi'an, Shaanxi, 716000, China
Yantai Yuhuangding Hospital
NOT_YET_RECRUITING

Yantai, Shandong, 264000, China
Yunnan Provincial Hospital of Chinese Medicine
NOT_YET_RECRUITING

Kunming, Yunnan, 650032, China
Zhejiang Provincial People's Hospital
NOT_YET_RECRUITING

Hangzhou, Zhejiang, 310014, China
Zhongnan Hospital of Wuhan University
NOT_YET_RECRUITING

Wuhan, Hubei, 430060, China
Zibo Central Hospital
NOT_YET_RECRUITING

Zibo, Shandong, 255036, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.